Synageva Biopharma (GEVA) Stock More Than Doubles to 52-Week High on Alexion Acquisition

NEW YORK (TheStreet) -- Shares of Synageva Biopharma  (GEVA) skyrocketed 125% to a 52-week high of $215.74 on Wednesday after Alexion Pharmaceuticals (ALXN) agreed to acquire it for $8.4 billion to widen Alexion's offering of rare disease treatments.

The cash-and-stock deal values Synageva at $230 a share based on Alexion's average closing price over the past nine days. This marks a 140% premium to Synageva's closing price of $95.87 on Tuesday.

Alexion agreed to pay $115 in cash and 0.6581 Alexion shares for every Synageva share.

The acquisition is an effort by Alexion to diversify from Soliris, the company's only marketed product. The company designed Soliris to treat two rare disorders: atypical hemolytic uremic syndrome and Paroxysmal nocturnal hemoglobinuria.

More than 10.1 million shares had changed hands as of 1:31 p.m., compared to the daily average volume of 1,241,030.

For more on this story, read Adam Feuerstein's in-depth coverage here.

GEVA Chart GEVA data by YCharts

More from Markets

Splunk Goes Splunk, Salesforce and Twilio Tumble as Cloud Stocks Fall

Splunk Goes Splunk, Salesforce and Twilio Tumble as Cloud Stocks Fall

The Market Is 'Full Blown Bear,' Says Jim Cramer

The Market Is 'Full Blown Bear,' Says Jim Cramer

Dow Drops More Than 400 Points, Nasdaq Drops Further Into Correction Territory

Dow Drops More Than 400 Points, Nasdaq Drops Further Into Correction Territory

Pot Stocks Are Getting Crushed Along With the Rest of the Market

Pot Stocks Are Getting Crushed Along With the Rest of the Market

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth